VERTEX PHARMACEUTICALS

(VRTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Vertex Pharmaceuticals Incorporated announces European Commission Approves KAFTRIO® (ivacaftor/tezacaftor/elexacaftor)

01/11/2022 | 03:01am EDT

Vertex Pharmaceuticals Incorporated announced that the European Commission has granted approval for the label extension of KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor for the treatment of cystic fibrosis (CF) in patients ages 6 through 11 years old who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. As a result of long-term reimbursement agreements in Austria, Northern Ireland and Denmark, and provisions for access in health care systems such as Germany, eligible patients in these countries will have access to the expanded indication for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor shortly following regulatory approval by the European Commission. Vertex will continue to work with reimbursement bodies across the European Union to ensure access for all eligible patients.


© S&P Capital IQ 2022
All news about VERTEX PHARMACEUTICALS
05/19Vertex Pharmaceuticals - Suketu Upadhyay Elected to Vertex Board of Directors
AQ
05/18VERTEX PHARMACEUTICALS INC / MA : Submission of Matters to a Vote of Security Holders (for..
AQ
05/18Suketu Upadhyay Elected to Vertex Board of Directors
BU
05/18Vertex Pharmaceuticals Incorporated Elects Suketu Upadhyay as Independent Director
CI
05/17Vertex Pharmaceuticals Pledges $50 Million to Health Equity
MT
05/17Vertex Announces Further Expansion in the Boston Seaport at Dedication of the Jeffrey L..
BU
05/17Vertex Pharmaceuticals Incorporated Announces Further Expansion in the Boston Seaport A..
CI
05/17Vertex Announces $50 Million Commitment to Health Equity With Three Initial Grants
BU
05/09UBS Adjusts Vertex Pharmaceuticals Price Target to $321 From $322, Maintains Buy Rating
MT
05/06VERTEX PHARMACEUTICALS INC / MA Management's Discussion and Analysis of Financial Cond..
AQ
More news
Analyst Recommendations on VERTEX PHARMACEUTICALS
More recommendations
Financials (USD)
Sales 2022 8 585 M - -
Net income 2022 3 253 M - -
Net cash 2022 10 823 M - -
P/E ratio 2022 20,2x
Yield 2022 -
Capitalization 65 333 M 65 333 M -
EV / Sales 2022 6,35x
EV / Sales 2023 5,48x
Nbr of Employees 3 900
Free-Float 99,6%
Chart VERTEX PHARMACEUTICALS
Duration : Period :
Vertex Pharmaceuticals Technical Analysis Chart | VRTX | US92532F1003 | MarketScreener
Technical analysis trends VERTEX PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 255,45 $
Average target price 294,18 $
Spread / Average Target 15,2%
EPS Revisions
Managers and Directors
Reshma Kewalramani President, Chief Executive Officer & Director
Charles F. Wagner Chief Financial Officer & Executive Vice President
Jeffrey M. Leiden Executive Chairman
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
Carmen Bozic Chief Medical Officer & EVP-Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
VERTEX PHARMACEUTICALS16.33%65 333
GILEAD SCIENCES, INC.-12.86%79 298
REGENERON PHARMACEUTICALS, INC.4.06%71 026
WUXI APPTEC CO., LTD.-19.12%41 409
BIONTECH SE-39.08%38 169
GENMAB A/S-19.16%19 651